Cinnamic acid

Pharmacology & Research

Cinnamic acid is the simple phenylpropenoic acid of cinnamon and sits at a branch point in plant biochemistry — formed from phenylalanine and serving as the unsubstituted backbone from which the hydroxycinnamic acids (caffeic, ferulic, p-coumaric) derive. Two identity points matter throughout: it is distinct from cinnamaldehyde (the aldehyde that carries most of cinnamon’s pharmacology) and, lacking a ring hydroxyl, it is a weaker antioxidant than its hydroxylated relatives. Its most notable isolate signal is antidiabetic, but all of it is preclinical — cinnamon’s human glucose data belong to the spice/aldehyde, not to this acid.

1. Antidiabetic / antihyperglycemic

Oral cinnamic acid improved glucose tolerance in type-2 diabetic rats and directly stimulated glucose-induced insulin secretion in isolated islets ^{1Reference 1Hafizur RM et al. · 2015In vitroCinnamic acid exerts anti-diabetic activity by improving glucose tolerance in vivo and stimulating insulin secretion in vitroView study →}; in adipocytes it raised adiponectin and the p-AMPK/AMPK ratio ^{3Reference 3Kopp T et al. · 2014trans-Cinnamic acid increases adiponectin and the p-AMPK/AMPK ratio in 3T3-L1 adipocytesView study →}, and a dedicated review compiles insulin-secretion, reduced gluconeogenesis and enhanced glucose uptake for the acid and its derivatives ^{2Reference 2Adisakwattana S · 2017Cinnamic acid and its derivatives: mechanisms for prevention and management of diabetes and its complicationsView study →}. (In-vitro work also reports apoptosis in melanoma cells, but only at millimolar concentrations far above achievable exposure ^{4Reference 4Niero EL · 2013Cinnamic acid induces apoptotic cell death and cytoskeleton disruption in human melanoma cellsView study →}.)

Gap: all rodent/in-vitro; no human trial of the isolate — cinnamon’s human glucose data belong to the spice and cinnamaldehyde, not to cinnamic acid ^{1,2Reference 1Hafizur RM et al. · 2015In vitroCinnamic acid exerts anti-diabetic activity by improving glucose tolerance in vivo and stimulating insulin secretion in vitroView study →Reference 2Adisakwattana S · 2017Cinnamic acid and its derivatives: mechanisms for prevention and management of diabetes and its complicationsView study →}.

2. Antioxidant

Free-radical scavenging is the property that put cinnamic acid on the page.

Gap: it lacks a phenolic ring hydroxyl, so it is a distinctly weaker antioxidant than its hydroxylated relatives, and most data are DPPH/ORAC-type chemical assays, not cellular or in-vivo endpoints ^{8,9Reference 82025ReviewPharmacological potential of cinnamic acid and derivatives: a comprehensive reviewView study →Reference 9Ruwizhi N · 2020Cinnamic acid derivatives and their biological efficacyView study →}.

3. Antimicrobial

Cinnamic acid is reviewed as an antibacterial/antifungal scaffold with membrane-permeabilising and antibiotic-potentiating behaviour ^{8Reference 82025ReviewPharmacological potential of cinnamic acid and derivatives: a comprehensive reviewView study →}.

Gap: intrinsic MICs are weak, and most potent antimicrobial activity sits in synthetic cinnamate esters/amides, not the free acid — some cited cinnamon-oil activity belongs to cinnamaldehyde ^{8Reference 82025ReviewPharmacological potential of cinnamic acid and derivatives: a comprehensive reviewView study →}.

4. Anti-inflammatory

Cinnamic acid reduces pro-inflammatory signalling (IκB phosphorylation → NF-κB) in LPS-stimulated macrophage models ^{9Reference 9Ruwizhi N · 2020Cinnamic acid derivatives and their biological efficacyView study →}.

Gap: much of the signal comes from derivatives or nanoparticle formulations rather than the free acid, with no in-vivo isolate confirmation of note ^{9Reference 9Ruwizhi N · 2020Cinnamic acid derivatives and their biological efficacyView study →}.

5. Tyrosinase / skin

Cinnamic acid acts as a mixed-type tyrosinase inhibitor in enzyme-kinetic studies ^{5Reference 5Chen QX et al. · 2010Tyrosinase-inhibitory activities of cinnamic acid analoguesView study →}.

Gap: purified-enzyme/in-vitro cosmetic interest only, with no skin-whitening or clinical dermatology evidence for the isolate ^{5Reference 5Chen QX et al. · 2010Tyrosinase-inhibitory activities of cinnamic acid analoguesView study →}.

Mechanisms

Target / pathway	Effect	Relevant to
Pancreatic β-cell insulin secretion	↑ glucose-stimulated insulin release (isolated islets)	antidiabetic
Adiponectin / AMPK (adipocytes)	↑ adiponectin, ↑ p-AMPK/AMPK	antidiabetic / metabolic
ROS / free radicals	radical scavenging (weak, no ring -OH)	antioxidant
NF-κB / IκB phosphorylation	↓ pro-inflammatory transcription	anti-inflammatory
Tyrosinase	mixed-type enzyme inhibition	skin / cosmetic

Pharmacokinetics

Cinnamic acid is orally absorbed and rapidly metabolised by hepatic/mitochondrial β-oxidation: activation to cinnamoyl-CoA, conversion to benzoyl-CoA and benzoic acid, then glycine conjugation to hippuric acid — the dominant urinary metabolite, accounting for the majority of an oral dose in humans ^{6,7Reference 6Hoskins JA · 1984The metabolism of cinnamic acid by healthy and phenylketonuric adults: a kinetic studyView study →Reference 7Nutley BP et al. · 1994AnimalMetabolism of trans-cinnamic acid in the rat and mouse and its variation with doseView study →}. Its short plasma half-life (well under an hour) and extensive first-pass conversion mean low sustained systemic exposure of the intact acid, a key limit on any systemic pharmacology. The pathway is consistent across rat, mouse and human and largely dose-independent ^{7Reference 7Nutley BP et al. · 1994AnimalMetabolism of trans-cinnamic acid in the rat and mouse and its variation with doseView study →}.

Clinical trials

There are no human trials of purified trans-cinnamic acid for any indication. Human cinnamon trials test the whole spice or extract and reflect cinnamaldehyde and other constituents — they cannot be attributed to cinnamic acid. The evidence base is preclinical (rodent, in-vitro, enzyme-kinetic) plus reviews.

Last checked: July 2026.

Toxicity & Safety

Cinnamic acid is a widespread dietary phenolic acid (fruits, vegetables, cinnamon, balsams, honey) and a long-standing GRAS flavour/fragrance ingredient. Its efficient β-oxidation to benzoic and hippuric acid is a detoxication route, and animal acute toxicity is low, with no notable safety concerns at dietary or flavour-use levels. A dedicated isolated-compound human toxicology dataset is limited, and the millimolar concentrations used in some cell studies are far above dietary exposure.

Pregnancy & lactation

Dietary amounts fine; avoid concentrated supplements. Cinnamic acid as present in food and spice requires no avoidance, but there is no isolate-specific reproductive-safety data, so concentrated or supplemental doses are not recommended in pregnancy or lactation.

Dosage

There is no established therapeutic human dose — cinnamic acid is not used as a stand-alone supplement, and human exposure is dietary (milligram quantities from cinnamon, fruit and other plant foods). Preclinical antidiabetic effects used rodent oral doses (roughly 5–30 mg/kg in the source studies) that do not translate to a validated human regimen; treat it as a dietary/flavour constituent and biochemical precursor, not a dosed intervention.

References